The pipeline in headache therapy

Sarah E. Vollbracht, Alan M. Rapoport

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Migraine is a common, disabling, neurovascular disorder characterized by episodic attacks of head pain and associated disability plus systemic autonomic and neurologic symptoms. The advent of the triptan class of medication in the 1990s revolutionized the acute treatment of migraine, but many migraineurs do not respond optimally or at all to triptans, have intolerable adverse effects, or have contraindications to their use. Preventive pharmacotherapy has advanced mostly through serendipity, with new drugs being found effective while being used for other indications. There remains a significant need for new medications and devices that can provide effective, rapid, and sustained pain relief without adverse effects or recurrence. Several new acute and preventive therapies for the treatment of migraine and cluster headaches have shown promise and are currently under investigation. This article covers innovative delivery mechanisms, calcitonin gene-related peptide receptor antagonists, antibodies to calcitonin gene-related peptide and its receptor, 5-HT1F receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neurostimulation.

Original languageEnglish (US)
Pages (from-to)717-729
Number of pages13
JournalCNS Drugs
Volume27
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Migraine Disorders
Calcitonin Gene-Related Peptide Receptors
Tryptamines
Headache
Cluster Headache
TRPV Cation Channels
Autonomic Nervous System
Neurologic Manifestations
Neuroglia
Therapeutics
Recurrence
Drug Therapy
Pain
Equipment and Supplies
Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

The pipeline in headache therapy. / Vollbracht, Sarah E.; Rapoport, Alan M.

In: CNS Drugs, Vol. 27, No. 9, 09.2013, p. 717-729.

Research output: Contribution to journalArticle

Vollbracht, Sarah E. ; Rapoport, Alan M. / The pipeline in headache therapy. In: CNS Drugs. 2013 ; Vol. 27, No. 9. pp. 717-729.
@article{795fc4ebbace463190f2693e0a3c4fda,
title = "The pipeline in headache therapy",
abstract = "Migraine is a common, disabling, neurovascular disorder characterized by episodic attacks of head pain and associated disability plus systemic autonomic and neurologic symptoms. The advent of the triptan class of medication in the 1990s revolutionized the acute treatment of migraine, but many migraineurs do not respond optimally or at all to triptans, have intolerable adverse effects, or have contraindications to their use. Preventive pharmacotherapy has advanced mostly through serendipity, with new drugs being found effective while being used for other indications. There remains a significant need for new medications and devices that can provide effective, rapid, and sustained pain relief without adverse effects or recurrence. Several new acute and preventive therapies for the treatment of migraine and cluster headaches have shown promise and are currently under investigation. This article covers innovative delivery mechanisms, calcitonin gene-related peptide receptor antagonists, antibodies to calcitonin gene-related peptide and its receptor, 5-HT1F receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neurostimulation.",
author = "Vollbracht, {Sarah E.} and Rapoport, {Alan M.}",
year = "2013",
month = "9",
doi = "10.1007/s40263-013-0090-x",
language = "English (US)",
volume = "27",
pages = "717--729",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "9",

}

TY - JOUR

T1 - The pipeline in headache therapy

AU - Vollbracht, Sarah E.

AU - Rapoport, Alan M.

PY - 2013/9

Y1 - 2013/9

N2 - Migraine is a common, disabling, neurovascular disorder characterized by episodic attacks of head pain and associated disability plus systemic autonomic and neurologic symptoms. The advent of the triptan class of medication in the 1990s revolutionized the acute treatment of migraine, but many migraineurs do not respond optimally or at all to triptans, have intolerable adverse effects, or have contraindications to their use. Preventive pharmacotherapy has advanced mostly through serendipity, with new drugs being found effective while being used for other indications. There remains a significant need for new medications and devices that can provide effective, rapid, and sustained pain relief without adverse effects or recurrence. Several new acute and preventive therapies for the treatment of migraine and cluster headaches have shown promise and are currently under investigation. This article covers innovative delivery mechanisms, calcitonin gene-related peptide receptor antagonists, antibodies to calcitonin gene-related peptide and its receptor, 5-HT1F receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neurostimulation.

AB - Migraine is a common, disabling, neurovascular disorder characterized by episodic attacks of head pain and associated disability plus systemic autonomic and neurologic symptoms. The advent of the triptan class of medication in the 1990s revolutionized the acute treatment of migraine, but many migraineurs do not respond optimally or at all to triptans, have intolerable adverse effects, or have contraindications to their use. Preventive pharmacotherapy has advanced mostly through serendipity, with new drugs being found effective while being used for other indications. There remains a significant need for new medications and devices that can provide effective, rapid, and sustained pain relief without adverse effects or recurrence. Several new acute and preventive therapies for the treatment of migraine and cluster headaches have shown promise and are currently under investigation. This article covers innovative delivery mechanisms, calcitonin gene-related peptide receptor antagonists, antibodies to calcitonin gene-related peptide and its receptor, 5-HT1F receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neurostimulation.

UR - http://www.scopus.com/inward/record.url?scp=84883259160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883259160&partnerID=8YFLogxK

U2 - 10.1007/s40263-013-0090-x

DO - 10.1007/s40263-013-0090-x

M3 - Article

C2 - 23839594

AN - SCOPUS:84883259160

VL - 27

SP - 717

EP - 729

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 9

ER -